Adamas Pharmaceuticals, Inc. is focused on the research, development, and commercialization of therapeutic solutions for individuals in the United States suffering from chronic neurological conditions. The company's marketed products include GOCOVRI, an extended-release capsule designed to treat dyskinesia in Parkinson's disease patients who are undergoing levodopa-based therapy, with or without other dopaminergic medications. Additionally, they provide Namzaric capsules, a combination of extended-release memantine hydrochloride and donepezil hydrochloride, used for managing moderate to severe Alzheimer's-type dementia. In its development pipeline, Adamas is progressing ADS-5102, which is currently undergoing Phase III clinical trials to address walking difficulties in patients with multiple sclerosis, among other potential applications. The firm has also completed two Phase I studies for ADS-4101, a candidate treatment for partial onset seizures in epilepsy patients. Founded in 2000, the company initially operated as NeuroMolecular Pharmaceuticals, Inc. before changing its name to Adamas Pharmaceuticals, Inc. in July 2007. Its corporate headquarters are located in Emeryville, California.